Hypera Pharma (B3:HYPE3)

Executive Summary

Hypera Pharma is one of Brazil's largest and most diversified pharmaceutical companies, with a robust portfolio spanning prescription drugs, over‑the‑counter (OTC) products, generics, dermatological skincare, and vitamins & supplements. The company leverages advanced formulation and manufacturing capabilities to deliver high‑quality, affordable medicines, serving a broad patient base across multiple therapeutic areas. Listed on B3 under ticker HYPE3, Hypera has established a strong domestic foothold through organic growth and strategic acquisitions, positioning itself as a key player in Brazil's expanding healthcare market. The company's focus on innovation, sustainable growth, and operational efficiency underpins its competitive advantage, while its diversified revenue streams reduce dependence on any single product or category. With a large commercial presence (1000+ employees) and a track record of consistent performance, Hypera is well‑placed to capitalize on Brazil's growing demand for healthcare, driven by an aging population and increased access to medicines. The company's public listing provides transparency and access to capital markets, supporting future expansion and R&D initiatives.

Upcoming Catalysts (preview)

• Q3 2026Launch of new OTC/dermatology products in Brazil70% success
• Q4 2026Potential acquisition of a niche pharma or generics company to expand portfolio50% success
• Q2 2026ANVISA approval for a novel prescription drug in metabolic or dermatology area40% success